advertisement
3.8 Pharmacology (117)
Showing records 1 to 25
Display all abstracts in classification 3.8 Pharmacology
Search within classification 3.8 Pharmacology77917 Resveratrol ameliorates disorders of mitochondrial biogenesis and dynamics in a rat chronic ocular hypertension model
Zhang X
Life Sciences 2018; 207: 234-245
77880 Targeting Serotonin 2A and Adrenergic α Receptors for Ocular Antihypertensive Agents: Discovery of 3,4-Dihydropyrazino1,2-bindazol-1(2H)-one Derivatives
Furlotti G
ChemMedChem 2018; 13: 1597-1607
78106 Retrobulbar hemodynamics and aqueous humor levels of endothelin-1 in exfoliation syndrome and exfoliation glaucoma
Koukoula SC
Clinical Ophthalmology 2018; 12: 1199-1204
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fuwa M
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78141 YAP/TAZ Are Essential for TGF-β2-Mediated Conjunctival Fibrosis
Futakuchi A
Investigative Ophthalmology and Visual Science 2018; 59: 3069-3078
78176 Therapeutic applications of cannabinoids
Maurya N
Chemico-biological interactions 2018; 293: 77-88
78025 Elevated Pressure Increases Ca Influx Through AMPA Receptors in Select Populations of Retinal Ganglion Cells
Wen X
Frontiers in cellular neuroscience 2018; 12: 162
78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Jacob TF
Purinergic signalling 2018; 14: 271-284
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891
77896 Trabecular meshwork ECM remodeling in glaucoma: could RAS be a target?
Agarwal P
Expert Opinion on Therapeutic Targets 2018; 22: 629-638
78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Mahalingam K
Indian Journal of Ophthalmology 2018; 66: 1104-1108
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78249 Protective effect of magnesium acetyltaurate and taurine against NMDA-induced retinal damage involves reduced nitrosative stress
Jafri AJA
Molecular Vision 2018; 24: 495-508
78128 Should ophtalmologists recommend medical cannabis to patients with glaucoma?
Mouhammad ZA
Ugeskrift for Laeger 2018; 180:
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Davis BM
Scientific reports 2018; 8: 11066
78240 Resveratrol Delays Retinal Ganglion Cell Loss and Attenuates Gliosis-Related Inflammation From Ischemia-Reperfusion Injury
Luo H
Investigative Ophthalmology and Visual Science 2018; 59: 3879-3888
78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Chaurasia AK
Indian Journal of Ophthalmology 2018; 66: 1104-1108
78128 Should ophtalmologists recommend medical cannabis to patients with glaucoma?
Kolko M
Ugeskrift for Laeger 2018; 180:
78141 YAP/TAZ Are Essential for TGF-β2-Mediated Conjunctival Fibrosis
Inoue T
Investigative Ophthalmology and Visual Science 2018; 59: 3069-3078
78187 Triptolide inhibits TGF-β-induced matrix contraction and fibronectin production mediated by human Tenon fibroblasts
Liu PP
International Journal of Ophthalmology 2018; 11: 1108-1113
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Pahlitzsch M
Scientific reports 2018; 8: 11066
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Toris CB
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
77880 Targeting Serotonin 2A and Adrenergic α Receptors for Ocular Antihypertensive Agents: Discovery of 3,4-Dihydropyrazino1,2-bindazol-1(2H)-one Derivatives
Alisi MA
ChemMedChem 2018; 13: 1597-1607
78240 Resveratrol Delays Retinal Ganglion Cell Loss and Attenuates Gliosis-Related Inflammation From Ischemia-Reperfusion Injury
Zhuang J
Investigative Ophthalmology and Visual Science 2018; 59: 3879-3888
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Tanaka M
Journal of Medicinal Chemistry 2018; 61: 6869-6891